18F-FES PET预测子宫内膜癌疾病结局的前瞻性研究
该前瞻性研究纳入67例FIGO I-IV期子宫内膜癌患者,治疗前行18F-FES和18F-FDG PET/CT,比较原发肿瘤SUVmean与临床特征及生存的关系。结果显示低18F-FES SUV与不良预后显著相关,且为PFS独立预后因素,而18F-FDG无显著差异。
要点
- 低18F-FES SUV与LVSI、淋巴结转移等预后因素显著相关。
- 低18F-FES SUV患者PFS和OS显著更差,18F-FDG无此差异。
- 18F-FES SUV<2.63是PFS独立预后因素(HR 10.727)。
核心结论
- 原发肿瘤低18F-FES SUV与子宫内膜癌LVSI和淋巴结转移等预后因素强相关。
- 低18F-FES SUV是子宫内膜癌患者PFS的独立预后因素。
- 治疗前18F-FES PET可能有助于确定子宫内膜癌患者的适宜治疗。
研究设计与样本
- 前瞻性研究纳入67例FIGO I-IV期子宫内膜癌患者。
- 治疗前均行18F-FES和18F-FDG PET/CT,比较原发肿瘤SUVmean与临床特征及生存。
主要发现
- 18F-FES SUV与分期、组织学、LVSI和淋巴结转移显著相关。
- 18F-FDG SUV与分期、肌层浸润、肿瘤大小和淋巴结转移显著相关。
- 18F-FES SUV检测肿瘤进展和生存的AUC分别为0.813和0.790,18F-FDG分别为0.557和0.635。
- 低18F-FES SUV患者PFS(P<0.001)和OS(P=0.001)显著更差,18F-FDG无显著差异。
- 低复发风险亚组27例中,低18F-FES SUV患者PFS仍更差(P=0.002)。
关键数值与推荐
- 多因素分析中18F-FES SUV<2.63与PFS显著相关(P=0.037;HR 10.727;95%CI 1.16-99.35)。
- FIGO III和IV期与PFS显著相关(P=0.042;HR 8.838;95%CI 1.09-71.84)。
临床怎么用
- 治疗前18F-FES PET可用于评估子宫内膜癌预后风险。
- 低18F-FES SUV提示不良预后,可能辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to evaluate the potential of 16α-18F-fluoro-17β-estradiol (18F-FES) PET to predict prognosis in patients with endometrial cancer (EC). Methods: In total, 67 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-IV EC underwent 18F-FES and 18F-FDG PET/CT before treatment. The SUVmean of the primary tumor was compared with the clinical characteristics, and the relationships between SUV and progression-free survival (PFS) or overall survival were analyzed. Results:18F-FES SUV was significantly associated with stage, histology, lymphovascular space involvement (LVSI), and lymph node metastasis, and 18F-FDG SUV was significantly associated with stage, myometrial invasion, tumor size, and lymph node metastasis. Receiver-operating characteristic curve analysis revealed that 18F-FES SUV could significantly detect tumor progression and survival, with areas under the curve of 0.813 and 0.790, respectively, whereas 18F-FDG SUV could detect them with areas under the curve of 0.557 and 0.635, respectively. The Kaplan-Meier survival curve showed that patients with a low 18F-FES SUV had significantly poor PFS (P < 0.001) and overall survival (P = 0.001) compared with patients with a high SUV, whereas 18F-FDG showed no significant differences. In a subanalysis of 27 patients with a low risk of recurrence (FIGO stage IA endometrioid carcinoma [grade 1 or 2] without LVSI), those with a low 18F-FES SUV also had poorer PFS than those with a high SUV (P = 0.002). In multivariate analysis, an 18F-FES SUV of less than 2.63 (P = 0.037; hazard ratio, 10.727; 95% CI, 1.16-99.35) and FIGO stages III and IV (P = 0.042; hazard ratio, 8.838; 95% CI, 1.09-71.84) were significantly associated with PFS. Conclusion: A low 18F-FES for the primary tumor was strongly associated with prognostic factors of EC such as LVSI and lymph node metastasis, and a low 18F-FES SUV was an independent prognostic factor for PFS in patients with EC. These data suggest that pretreatment 18F-FES PET might be useful in determining the appropriate treatment for patients with EC.
引用
- Yamada S, Tsuyoshi H, Yamamoto M, et al. Prognostic Value of 16α-18F-Fluoro-17β-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study. J Nucl Med. 2020. PMID: 33008930. doi:10.2967/jnumed.120.244319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。